Indaptus Therapeutics, Inc.
NASDAQ:INDPBiotechnology
-$0.03 today
- Market cap
- $375.96M
- Beta
- 1.14
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.70
Volume 0.28M
Average 0.97M
Returns on capital
Indaptus Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-661.5%
avg -33.1%
ROIC
-629.3%
avg -16.7%
ROA
-223.9%
avg -110.6%
Analysis
ROA is currently the strongest return metric at -223.9% versus its period average of -110.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Junyi Dai | CEO & Chairman | — | 39 | 11.25M | 9.93% |
Yu Ding | Chief Financial Officer | — | 51 | — | — |
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 23, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
2
$0.00
Net Transaction Value
Neutral
Balanced transaction value
Most Active
Lazar David E.
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Mar 23, 26Mar 23, 2026 | Lazar David E. Direct | Sell | $0$0.00 |
| Mar 23, 26Mar 23, 2026 | Lazar David E. Direct | Sell | $0$0.00 |
Summary
Insiders reported 0 buys worth $0.00 and 2 sells worth $0.00 over the last 12 months. Reported purchase and sale values were balanced. Lazar David E. was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Indaptus Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about INDP's management, answered from reported figures.
Who manages INDP?
Indaptus Therapeutics, Inc. (INDP) lists 2 active executives. The top listed executive is Junyi Dai, CEO & Chairman.
Are INDP insiders buying or selling?
Recent insider activity shows net buying of $14.43M.
Continue the stock analysis
Jump to another research area for this company.